Scleroderma | Boehringer Ingelheim

Scleroderma

Systemic sclerosis (SSc) is a disfiguring, disabling and potentially fatal rare disease that causes scarring of the skin (scleroderma), lungs (SSc-ILD) and other organs. Worldwide it is estimated that over two million people have systemic sclerosis and it affects mostly women in the prime of their lives, between 25 and 55 years of age. Systemic sclerosis is a complex rare disease with a variable course. It presents with a range of symptoms involving several different organs; this means it is difficult to recognize and this can delay early and accurate diagnosis.

Nurjanah’s story

How a rare disease brought the Bruggeman family together

[Read more](/content/human-health/lung-diseases/scleroderma/nurjanahs-story "Teaser headline Nurjanah’s story"/index.html)

Scleroderma Life Hacks

Video series featuring people living with scleroderma using everyday items in different ways to help them manage their symptoms.

[Read more](/content/human-health/lung-diseases/scleroderma/scleroderma-life-hacks "Scleroderma Life Hacks"/index.html)

All eyes on patients

EURORDIS has selected Boehringer Ingelheim for the first time as recipient of the prestigious Black Pearl Award 2020

[Read more](/content/human-health/lung-diseases/scleroderma/eurordis-award "EURORDIS Award"/index.html)

The little things

In 2009 Anna was diagnosed with scleroderma. For her, however, the disease is no reason to give up. On the contrary.

[Read more](/content/human-health/lung-diseases/scleroderma/little-things "The little things"/index.html)

Further Topics

In this new video listen to consultant rheumatologist Professor Denton discuss his experience diagnosing systemic sclerosis.

Systemic Sclerosis ILD Infographic

Facts and information about Systemic Sclerosis Interstitial Lung Disease

[Download the infographic](/content/sites/default/files/Prescription_Medicine/respiratory_prescription_medicine/systemic_sclerosis_respiratory_prescription_medicine/786210066%20-%20SSc_INFOGRAPHIC_CC06.pdf "Systemic Sclerosis ILD Infographic"/index.html)

Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease

[Read more](/content/human-health/lung-diseases/scleroderma/inpedildtrialenrollment "Read more about "Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease""/index.html)